Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15343497 | 0.83 | LMNA (0.32) | LMNAGAA | |
| SCHEMBL15343495 | 0.80 | LMNA (0.30) | LMNAGAA | |
| SCHEMBL15339825 | 0.80 | — | — | |
| SCHEMBL15339820 | 0.79 | — | — | |
| SCHEMBL14458078 | 0.77 | LMNA (0.33) | LMNAGAA | |
| SCHEMBL15343499 | 0.76 | — | — | |
| SCHEMBL15343500 | 0.73 | — | — | |
| SCHEMBL12825236 | 0.69 | — | — | |
| SCHEMBL15339816 | 0.69 | — | — | |
| SCHEMBL15339824 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249128-B2 | Anti-cancer serine hydrolase inhibitory carbamates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-02-02 | — | — | US | disclosed |
| US-9140836-B2 | Method of shielding ultraviolet light and increasing visible light, and ultraviolet-light-shielding and visible-light-increasing material which enables implementation of the method | TELEFONAKTIEBOLAGET L M ERICSSON (PUBL) (SE) | 2015-09-22 | — | — | US | disclosed |
| US-9140836-B2 | Method of shielding ultraviolet light and increasing visible light, and ultraviolet-light-shielding and visible-light-increasing material which enables implementation of the method | TELEFONAKTIEBOLAGET L M ERICSSON (PUBL) (SE) | 2015-09-22 | — | — | US | disclosed |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130221239-A1 | METHOD OF SHIELDING ULTRAVIOLET LIGHT AND INCREASING VISIBLE LIGHT, AND ULTRAVIOLET-LIGHT-SHIELDING AND VISIBLE-LIGHT-INCREASING MATERIAL WHICH ENABLES IMPLEMENTATION OF THE METHOD | TELEFONAKTIEBOLAGET L M ERICSSON (PUBL) (SE) | 2013-08-29 | — | — | US | disclosed |
| US-20130221239-A1 | METHOD OF SHIELDING ULTRAVIOLET LIGHT AND INCREASING VISIBLE LIGHT, AND ULTRAVIOLET-LIGHT-SHIELDING AND VISIBLE-LIGHT-INCREASING MATERIAL WHICH ENABLES IMPLEMENTATION OF THE METHOD | TELEFONAKTIEBOLAGET L M ERICSSON (PUBL) (SE) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | AADAC, DDAH1, PRSS1 | LMNA 4450/4885GAA 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.